Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up

Table 1 Proviral DNA at baseline (week 0) and weeks 12, 24 and 48 after rhGH immunotherapy.

Proviral DNA, HIV-1 copy number/μg of total DNA
Patient^a	Baseline	Week 12	Week 24	Week 48
1 B	ND	8	ND	16
2 C	111	17	ND	46
3 C	476	853	711	625
4 B	536	452	307	220
5 A	55	46	50	52
6 A	223	359	99	93
7 C	315	150	83	238
8 B	42	83	28	57
9 B	91	103	35	56
10 C	15	1212*	750*	ND
11 A	363	3926*	1830*	2277*
12 A	48	27	336*	138
Mean ± sem	206 ± 56.6	603 ± 321.3	433 ± 178.2	347 ± 199.9
Median	111	127	203	93
(Range)	(15–536)	(8–3926)	(28–1830)	(16–2277)

^a Randomisation group at week 12 to 24: A – placebo recipients; B – alternate day dosing; and C – twice weekly dosing. ND – Not Done. *Notable increase.